VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

By T. Voron, O. Colussi, E. Marcheteau, S. Pernot, M. Nizard, Anne-Laure Pointet, Sabrina Latreche, S. Bergaya, N. Benhamouda, Corinne Tanchot and 8 more. Journal of Experimental Medicine, 2015

1,071 citations recorded by the source corpus.

VEGF-A production in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved with CD8+ T cell exhaustion, which can be reversed with anti-VEGF/VEGFR treatment.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/fc65868002d71ab8312b74661ed833efab1cc51c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Oliver Kepp
5. A. Buqué
6. E. Henke
7. M. Smyth
8. V. Schirrmacher

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Oliver Kepp
5. S. Ergün
6. E. Henke
7. R. Nandigama
8. Rebecca S. Y. Wong

Citations in the corpus

• Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy (2020, background): “reported that VEGF-A promotes immune escape by inducing Tregs and causing PD1 expression on VEGF-R2 expressing CD8 T cells (Voron et al., 2015).”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “Most likely, this is related to the ability of VEGFA to stimulate the expression of immunosuppressive molecules on CTLs (Voron et al., 2015), placing the VEGF system (which until now has Cancer Cell 28, December 14, 2015 ª2015 Elsevier Inc. 705 Cancer Cell Review been harnessed as an antiangiogenic…”